How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/doxorubicin-hydrochloride-liposome-injection-carboplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Doxorubicin Hydrochloride Liposome Injection+carboplatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Doxorubicin Hydrochloride Liposome Injection+carboplatin (Doxorubicin Hydrochloride Liposome Injection+carboplatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy (anthracycline + platinum agent). Area: Oncology.

phase 3 Combination chemotherapy (anthracycline + platinum agent) DNA (topoisomerase II for doxorubicin; DNA adducts for carboplatin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Doxorubicin Hydrochloride Liposome Injection+carboplatin (Doxorubicin Hydrochloride Liposome Injection+carboplatin) — Hunan Cancer Hospital. Doxorubicin liposome intercalates DNA to inhibit topoisomerase II while carboplatin forms DNA cross-links, together inducing apoptosis in cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Doxorubicin Hydrochloride Liposome Injection+carboplatin TARGET	Doxorubicin Hydrochloride Liposome Injection+carboplatin	Hunan Cancer Hospital	phase 3	Combination chemotherapy (anthracycline + platinum agent)	DNA (topoisomerase II for doxorubicin; DNA adducts for carboplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy (anthracycline + platinum agent) class)

Hunan Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Doxorubicin Hydrochloride Liposome Injection+carboplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/doxorubicin-hydrochloride-liposome-injection-carboplatin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab